We assessed the therapeutic efficacy of the MMP2/9 inhibitor SB-3CT in combination with the anti-CTLA-4 antibody in two tumor models, B16F10 melanoma (Fig. 6a, Additional file 1: Fig. S6A) and LLC (Fig. 6b, Additional file 1: Fig. S6B). This evidence concerns the gene MMP2 and melanoma.